EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas

Federica Guffanti iD, Ilaria Mengoli, Francesca Ricci iD, Ludovica Perotti, Elena Capellini iD, Laura Sala, Simone Canesi iD, Chu-Chiao Wu iD, Robert Fruscio iD, Maya Ridinger iD, Giovanna Damia iD, Michela Chiappa iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26125708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Federica Guffanti und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Gynecological Preclinical Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Mila…. Hauptthemen laut MEDLINE: Piperazines, Pyrazoles, Quinazolines, Ovarian Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant form Cardiff Oncology, Cardiff Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Platinum resistance represents an urgent medical need in the management of ovarian cancer. The activity of the combinations of onvansertib, an inhibitor of polo-like kinase 1, with gemcitabine or carboplatin was tested using patient-derived xenografts of high-grade serous ovarian carcinoma resistant to cisplatin (DDP). Two PDX models were selected from our xenobank: one with acquired resistance to DDP (#266R) and the other (#315) with intrinsic DDP resistance. Tumor-bearing mice were randomized to receive vehicle, single onvansertib, gemcitabine and carboplatin, and their combinations. Onvansertib/gemcitabine and onvansertib/carboplatin combinations were well tolerated. In the #266R model, single drug treatments were completely inactive, while the combinations of onvansertib/gemcitabine and onvansertib/carboplatin resulted in a significant increase in survival compared to controls and single drugs (p < 0.001 versus control, onvansertib, gemcitabine and carboplatin). Similar efficacy was observed in the s.c. #315 PDX model; indeed, onvansertib and carboplatin monotherapies were inactive, gemcitabine monotherapy was marginally active, while both combinations were highly active. The molecular mechanism underlying the efficacy of the combinations suggests a higher induction of DNA damage which seems plausible considering that, in both cases, gemcitabine and carboplatin, respectively, interfere with DNA metabolism and induce alkylation damage. The results suggest that the combinations of onvansertib/gemcitabine and onvansertib/carboplatin are safe and were shown to be of therapeutic value in the platinum-resistant setting of ovarian carcinoma, strongly supporting their clinical translatability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperazinesPyrazolesQuinazolinesOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmHumansFemaleAnimalsMiceMice, NudeGemcitabineCarboplatinPlatinumDNA Damage

Stichwörter der Autor:innen

carboplatingemcitabineonvansertibovarian carcinomaplatinum resistanceplk1

Substanzen

onvansertibPiperazinesPyrazolesQuinazolinesGemcitabineCarboplatinPlatinum

Autor:innen und Institutionen

  • Laboratory of Gynecological Preclinical Oncology, Experimental Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
  • Mouse & Animal Pathology Laboratory (MAPLab), Fondazione UniMi, 20139 Milano, Italy.
  • Department of Veterinary Medicine and Animal Sciences, University of Milano, 20122 Lodi, Italy.
  • R&D Department, Cardiff Oncology, San Diego, CA 92121, USA.
  • UO Gynecology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
  • Department of Medicine and Surgery, University of Milan-Bicocca, 20126 Milan, Italy.

ORCID-Profile: Federica Guffanti, Francesca Ricci, Elena Capellini, Simone Canesi, Chu-Chiao Wu, Robert Fruscio, Maya Ridinger, Giovanna Damia, Michela Chiappa

Förderung

  • Grant form Cardiff Oncology
  • Cardiff Oncology

Zitieren

APA

Guffanti, F., Mengoli, I., Ricci, F., Perotti, L., Capellini, E., Sala, L., Canesi, S., Wu, C. C., Fruscio, R., Ridinger, M., Damia, G., & Chiappa, M. (2025). Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125708

Vancouver

Guffanti F, Mengoli I, Ricci F, Perotti L, Capellini E, Sala L, et al. Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125708

BibTeX
@article{Guffanti2025,
  author = {Guffanti, Federica and Mengoli, Ilaria and Ricci, Francesca and Perotti, Ludovica and Capellini, Elena and Sala, Laura and Canesi, Simone and Wu, Chu-Chiao and Fruscio, Robert and Ridinger, Maya and Damia, Giovanna and Chiappa, Michela},
  title = {Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26125708}
}
Kostenlos starten →